

Title: Sex differences between females and males in antipsychotic medication efficacy and adverse effects in the treatment of schizophrenia

Short title: Sex differences and antipsychotics

Journal: CNS Drugs

Authors:

Megan Galbally^{1,2} ORCID [0000-0003-3909-1918](https://orcid.org/0000-0003-3909-1918)

Karen Wynter^{1,3} ORCID [0000-0003-4620-7691](https://orcid.org/0000-0003-4620-7691)

Dan Siskind^{4,5} ORCID [0000-0002-2072-9216](https://orcid.org/0000-0002-2072-9216)

Christoph U. Correll^{6,7,8,9} ORCID [0000-0002-7254-5646](https://orcid.org/0000-0002-7254-5646)

Korinne Northwood^{4,5} ORCID [0000-0001-6268-547X](https://orcid.org/0000-0001-6268-547X)

Susanna Every-Palmer¹⁰ ORCID [0000-0001-6455-9741](https://orcid.org/0000-0001-6455-9741)

Affiliations:

1. School of Clinical Sciences, Monash University, Australia
2. Health Futures Institute, Murdoch University, Australia
3. Faculty of Health, Deakin University, Australia
4. Faculty of Medicine, The University of Queensland, Brisbane, Australia
5. Metro South Addiction and Mental Health Hospital and Health Service, Brisbane, Australia
6. Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
7. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
8. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
9. German Center for Mental Health (DZPG), partner site Berlin, Germany
10. Department of Psychological Medicine, University of Otago Wellington, New Zealand

Address Correspondence to: Professor Megan Galbally, megan.galbally@monash.edu

Supplementary Table 8: Changes in laboratory indicators from Baseline to End-of-Phase by sex, by treatment group collected non-fasting

		Women			Men			<i>p</i> ¹	<i>d</i>	
		Total n	Mean	SD	n	Mean	SD			n
Olanzapine	Glucose (MG/DL)	224	15.37	58.96	63	2.03	49.39	161	0.500	-0.045
	Triglycerides (MG/DL)	226	10.95	74.38	64	14.00	156.52	162	0.991	-0.001
	Total Cholesterol (MG/DL)	226	-4.77	39.06	64	2.68	38.63	162	0.225	0.081
	Prolactin (NG/ML)	224	-14.80	29.52	64	-4.93	12.37	160	0.190	1.31
Perphenazine	Glucose (MG/DL)	183	0.11	27.75	44	0.33	34.19	138	0.914	-0.008
	Triglycerides (MG/DL)	183	8.82	76.84	44	-1.94	213.69	139	0.281	-0.080
	Total Cholesterol (MG/DL)	183	3.73	40.60	44	-7.79	36.10	139	0.166	-0.102
	Prolactin (NG/ML)	173	-6.75	41.82	42	0.10	17.29	131	0.061	0.142
Quetiapine	Glucose (MG/DL)	223	3.54	24.39	48	-2.79	44.60	174	0.517	-0.044
	Triglycerides (MG/DL)	222	32.31	201.01	48	-21.83	191.49	174	0.168	-0.093
	Total Cholesterol (MG/DL)	222	4.33	35.45	48	-4.44	40.00	174	0.224	-0.082
	Prolactin (NG/ML)	218	-21.24	34.97	49	-5.73	15.47	169	0.004	0.193
Risperidone	Glucose (MG/DL)	231	2.53	30.97	61	2.20	36.67	169	0.634	0.031
	Triglycerides (MG/DL)	230	-12.45	95.69	62	-22.89	115.74	168	0.563	-0.038

	Total Cholesterol (MG/DL)	230	-8.56	46.16	62	-10.32	35.28	168	0.213	-0.082
	Prolactin (NG/ML)	220	23.89	37.94	61	6.16	16.20	159	<0.001	-0.266
Ziprasidone	Glucose (MG/DL)	113	-1.17	73.62	29	-4.60	41.84	83	0.118	-0.148
	Triglycerides (MG/DL)	113	-46.28	162.44	29	-39.07	114.12	84	0.428	-0.075
	Total Cholesterol (MG/DL)	113	-24.14	68.14	29	-15.92	74.27	84	0.411	0.077
	Prolactin (NG/ML)	114	-8.13	27.92	31	-3.59	15.85	83	0.206	0.118

¹ *p*-values and effect sizes associated with Mann-Whitney U tests